Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 12500 anti-xa iu - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 15000 anti-xa iu - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 18000 anti-xa iu - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - dalteparin sodium - injection - 25000 iu/ml - dalteparin sodium 25000 iu/ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - dalteparin sodium - injection - 10000 iu/ml - dalteparin sodium 10000 iu/ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - dalteparin sodium - injection - 10000 iu/ml - dalteparin sodium 10000 iu/ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - dalteparin sodium - injection - 2500 iu/0.2 ml - dalteparin sodium 2500 iu/0.2 ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - dalteparin sodium - injection - 2500 iu/ml - dalteparin sodium 2500 iu/ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - dalteparin sodium - injection - 5000 iu/0.2 ml - dalteparin sodium 5000 iu/0.2 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 10000 anti-xa iu/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.